Stocks To Buy Now

Blog


Grey Cloak Tech, Inc. (GRCK) Uplists to OTCQB Venture Market, Ticker Symbol Remains GRCK

  • GRCK develops high technology, cloud-based software designed to detect online fraud
  • Company owns proprietary FraudLytic™ digital platform that monitors internet traffic in real time
  • CFO said uplisting will raise visibility of GRCK to investment community, grow company

Grey Cloak Tech, Inc. (OTCQB: GRCK) has been uplisted to the OTCQB Venture Market (http://dtn.fm/3IIb3), but its ticker symbol remains unchanged at GRCK, the company announced. William Bossung, CFO, said that the uplisting would help raise the exposure of the company to the investment community. The change is effective immediately.

GRCK is a Las Vegas, Nevada-based company that develops high technology software designed to overcome the impact of costly digital threats. It is also designed to eliminate online fraud. It manufactures FraudLytic™, a cloud-based proprietary digital platform that monitors internet traffic in real time. This platform is specifically designed to prevent digital advertisers from online sites wrongly claiming the number of clicks to internet advertisers.

“Trading on the OTCQB will raise visibility of Grey Cloak Tech in the investment community,” Bossung said. “It’s an important step towards building Grey Cloak Tech into a larger company. We are pleased with this key improvement in the market positioning of our organization.”

OTCQB is a venture market designed for early stage and developing U.S. and international companies, GRCK said. To be eligible to join, firms must be current in their financial reporting and annually submit to a verification and to a management certification process.

For more information, visit the company’s website at www.GreyCloakTech.com

From Our Blog

Soligenix Inc. (NASDAQ: SNGX) Driving Innovation in Photodynamic Therapy Potential in Oncology, Dermatology

February 10, 2026

From lab research to clinical application, photodynamic therapy (“PDT”) is emerging as a powerful treatment approach that uses light and chemistry to selectively target diseased tissue. As this modality gains attention for its precision and safety profile, Soligenix (NASDAQ: SNGX) is developing light-activated therapies designed to treat cutaneous T-cell lymphoma (“CTCL”) and other inflammatory skin […]

Rotate your device 90° to view site.